However, a direct effect of SGLT-2 inhibitors on the mobilization of EPCs has not been demonstrated [39] and the use of SGLT-2 inhibitors and GLP-1 analogs as an adjuvant therapy for T1DM is currently not approved. This evidence concerns the gene GLP1R and type 1 diabetes mellitus.